News

News

September 25, 2018
AnaptysBio Announces Pricing of Public Offering of Common Stock
SAN DIEGO , Sept. 25, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the pricing of its underwritten public offering of 2,200,000
September 24, 2018
AnaptysBio Announces Proposed Public Offering of Common Stock
SAN DIEGO , Sept. 24, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that it intends to offer $200.0 million of its common stock in
August 6, 2018
AnaptysBio to Present at the 2018 Wedbush PacGrow Healthcare Conference

SAN DIEGO , Aug. 06, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio , will

May 30, 2018
AnaptysBio to Present at the Jefferies 2018 Global Healthcare Conference

SAN DIEGO , May 30, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio , will

Displaying 1 - 10 of 16